Incyte (INCY) EPS (Diluted) Growth (3y) (2013 - 2026)
Powered by 
Analysis
Incyte (INCY) EPS (Diluted) Growth (3y) (2013 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | 7.01% |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.90% |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | 82.91% |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 18.44% |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | - |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | 36.83% |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 36.39% |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -36.81% |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 67.51% |
| 10 | Incyte | 25.57 Bn | 21.03 Bn | 1.57 Bn | 46.09% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 46.09% |
| Mar 31, 2026 | 147.95% |
| Dec 31, 2025 | 127.24% |
| Sep 30, 2025 | 61.16% |
| Jun 30, 2025 | 41.34% |
| Mar 31, 2025 | 67.32% |
| Dec 31, 2024 | -27.80% |
| Sep 30, 2024 | -12.73% |
| Jun 30, 2024 | -71.34% |
| Mar 31, 2024 | 45.69% |
| Dec 31, 2023 | 9.01% |
| Sep 30, 2023 | 134.52% |
| Jun 30, 2023 | -11.85% |
| Mar 31, 2023 | 26.60% |
| Dec 31, 2022 | -37.07% |
| Sep 30, 2022 | -5.12% |
| Jun 30, 2022 | 14.23% |
| Mar 31, 2022 | -28.76% |
| Dec 31, 2021 | 99.39% |
| Sep 30, 2021 | 82.24% |